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SHORT REPORT Open Access
Genome-wide DNA methylation profiling of
CD8+ T cells shows a distinct epigenetic
signature to CD4+ T cells in multiple
sclerosis patients
Vicki E. Maltby1,2†, Moira C. Graves1,3†, Rodney A. Lea1,4, Miles C. Benton4, Katherine A. Sanders1,5, Lotti Tajouri5,
Rodney J. Scott1,6 and Jeannette Lechner-Scott1,3,7*
Abstract
Background: Multiple sclerosis (MS) is thought to be a T cell-mediated autoimmune disorder. MS pathogenesis is
likely due to a genetic predisposition triggered by a variety of environmental factors. Epigenetics, particularly DNA
methylation, provide a logical interface for environmental factors to influence the genome. In this study we aim to
identify DNA methylation changes associated with MS in CD8+ T cells in 30 relapsing remitting MS patients and 28
healthy blood donors using Illumina 450K methylation arrays.
Findings: Seventy-nine differentially methylated CpGs were associated with MS. The methylation profile of CD8+ T
cells was distinctive from our previously published data on CD4+ T cells in the same cohort. Most notably, there was
no major CpG effect at the MS risk gene HLA-DRB1 locus in the CD8+ T cells.
Conclusion: CD8+ T cells and CD4+ T cells have distinct DNA methylation profiles. This case–control study highlights
the importance of distinctive cell subtypes when investigating epigenetic changes in MS and other complex diseases.
Keywords: Multiple sclerosis, DNA methylation, CD8+ T cells, HLA-DRB1
Findings
Multiple sclerosis (MS) susceptibility is influenced by a
combination of genetic factors and environmental expo-
sures. CD4+ T cells have long been favoured as the most
important immune cell subset in the pathogenesis of
disease, but there is increasing evidence that CD8+ T
cells play a substantial role in central nervous system
damage (reviewed in [1]).
Despite several large genome-wide association studies
(GWAS), there remains a large proportion of unex-
plained heritability in terms of MS risk. Epigenetics can
influence the genome without changes to the DNA se-
quence. Environmental exposures such as smoking and
vitamin D levels have been demonstrated to modify epi-
genetic mechanisms, providing a plausible link between
environmental factors and disease [2, 3]. One such epi-
genetic mechanism is DNA methylation, which is the
addition of a methyl group to CpG dinucleotides. We,
and others, have used genome-wide DNA methylation
technologies to assess differentially methylated regions
(DMRs) of CD4+ T cells in MS patients compared to
healthy controls [4–6]. We found a striking methylation
signal located on chromosome 6p21 with a peak signal
at HLA-DRB1, which remained after controlling for
background SNP effects, as well as 55 non-HLA CpGs
that localise to genes previously linked with MS.
In an effort to determine if these previously identified
DMRs were specific to CD4+ T cells, we performed a
genome-wide methylation study of CD8+ T cells using
the same cohort, workflow and data analysis as de-
scribed in our previous study [5]. Briefly, DNA from
total CD8+ T cells was extracted from 30 MS patients
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and 28 healthy age- and sex-matched controls. The DNA
was bisulphite-converted and hybridised to Illumina 450K
arrays. Raw fluorescence data were processed using a
combination of R/Bioconductor and custom scripts of a
total of 442,672 probes representing individual CpG sites
that passed quality control (QC) steps. These CpGs were
analysed by statistical modelling of methylation levels
(β values) between MS cases and controls.
Figure 1 shows the genome-wide distribution of differ-
ential methylation scores for all CpG sites that passed
the nominal p value cut-off of 0.05. We conducted a
stepwise prioritisation strategy to extract the most ro-
bust CpG loci associated with MS. Based on the criteria
of (i) FDR p < 0.05 and (ii) Δmeth ≥ ± 0.1 thresholds, 111
CpGs were extracted. To filter out potential effects of
gender and treatment, we performed a subgroup analysis
of the methylation statistics as previously described [5].
This process reduced the number of associated CpG
sites down to a core panel of 79 (Table 1).
Of the 79 CpGs showing differential methylation in
MS patients after filtering, all resided outside the MHC
locus on chr 6p21. Of these, 27 were intergenic (34 %),
have no gene association, or map to genes of unknown
function. Of the remaining 52 loci, 26 % are promoter
associated, 9 % are in the 5′UTR, 5 % are in the 1st
exon, 20 % are in gene bodies and 8 % are in the 3′UTR.
Interestingly, none of these CpGs maps to genes that
have previously been reported to have a relationship
with MS [7, 8]. There was no overlap between these re-
sults and our previous results, and, unlike in CD4+ T
cells, there was no gene that contained multiple differen-
tially methylated sites. MORN1 has a single hypermethy-
lated CpG in both CD4+ and CD8+ T cells; however, it
was a different site in each study, making it unlikely that
this is a significant finding. Our observations are consistent
with the recent study by Bos et al., who also identified min-
imal overlap between the methylation profiles of CD4+
and CD8+ T cells of MS patients [4].
Using GSEA with WebGestalt, our patient cohort did
not have prominent pathways in the KEGG Pathway
analysis or disease association analysis. The most signifi-
cant promoter associated with differential methylation
was the ferritin light chain (FTL) gene. The MS cohort
displayed decreased methylation at this CpG locus
compared to controls. The gene’s biological function
is cation transport. One of the statistically significant
genes, ERG (ETS-related gene), had a single hyper-
methylated CpG in the MS cohort compared to controls.
ERG is a member of the transcription factor family in-
volved in activities such as cell proliferation, differentiation,
Fig. 1 A genome-wide differential methylation plot based on sites passing a nominal p value of 0.05. Data points outside the circle represent
increased methylation in multiple sclerosis (MS) patients compared to controls (i.e. Δmeth), whereas points inside the circle represent methylation
in the MS group
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Table 1 MS-associated CpGs in CD8+ T cells
Probe IDa CHRb Position Genec Feature Median (case) Median (control) Δmeth
d p valuee
cg03431738 21 40031295 ERG 5′UTR 0.81 0.68 0.13 0.004033
cg12026095 19 49468461 FTL TSS200 0.30 0.49 −0.18 0.004033
cg26228123 14 73392919 DCAF4 TSS200 0.09 0.20 −0.11 0.004033
cg10478035 13 80919503 - 0.75 0.64 0.11 0.004033
cg04474988 10 131770171 - 0.34 0.46 −0.11 0.03549
cg25152348 22 50946712 NCAPH2 1st exon 0.30 0.47 −0.17 0.03549
cg08206623 11 2907334 CDKN1C TSS1500 0.29 0.44 −0.15 0.004033
cg13738615 9 109624741 ZNF462 TSS1500 0.18 0.31 −0.13 0.004033
cg01525244 22 39548611 CBX7 TSS200 0.14 0.24 −0.10 0.004033
cg12702165 12 95228136 MIR492 TSS200 0.65 0.54 0.11 0.004033
cg06443542 10 100206752 HPS1 TSS200 0.14 0.25 −0.11 0.03549
cg00380172 6 148663585 SASH1 TSS200 0.21 0.33 −0.12 0.03549
cg19095187 6 108437051 - 0.17 0.31 −0.14 0.03549
cg04488145 3 46899455 MYL3 3′UTR 0.83 0.73 0.11 0.03549
cg03027241 20 49620453 KCNG1 3′UTR 0.50 0.32 0.18 0.004033
cg11700985 10 82127205 DYDC2 3′UTR 0.85 0.74 0.11 0.03549
cg07886142 5 126793022 MEGF10 3′UTR 0.59 0.46 0.13 0.03549
cg18183163 2 171574141 SP5 3′UTR 0.12 0.26 −0.14 0.03549
cg01181415 12 16757954 LMO3 5′UTR 0.22 0.36 −0.14 0.03549
cg10143811 12 16757985 LMO3 5′UTR 0.12 0.22 −0.10 0.03549
cg23274123 1 229478617 C1orf96 5′UTR 0.10 0.22 −0.12 0.004033
cg00095276 5 1068111 SLC12A7 Body 0.77 0.63 0.15 0.004033
cg03447557 1 2273735 MORN1 Body 0.80 0.70 0.10 0.03549
cg02745847 17 47075880 IGF2BP1 Body 0.17 0.31 −0.13 0.03549
cg09406795 11 64019655 PLCB3 Body 0.25 0.38 −0.13 0.000358
cg18016288 13 95834131 ABCC4 Body 0.47 0.32 0.15 0.000358
cg14486346 2 102000131 CREG2 Body 0.78 0.66 0.12 0.03549
cg21937244 14 103406412 CDC42BPB Body 0.75 0.61 0.14 0.03549
cg11811840 2 234669166 UGT1A10 Body 0.84 0.72 0.12 0.03549
cg25756617 1 43734917 TMEM125 TSS1500 0.69 0.58 0.11 0.03549
cg03768916 10 49813307 ARHGAP22 TSS200 0.30 0.43 −0.14 0.004033
cg06524757 13 72441523 DACH1 TSS200 0.25 0.35 −0.11 0.03549
cg03168749 11 124413574 OR8B12 TSS200 0.82 0.68 0.14 0.03549
cg21276022 9 136390236 TMEM8C TSS200 0.74 0.61 0.13 0.004033
cg09851596 8 143545214 BAI1 TSS200 0.60 0.49 0.11 0.03549
cg25296222 11 2037173 - 0.76 0.65 0.11 0.03549
cg00878533 1 2848864 - 0.72 0.62 0.11 0.000358
cg03612700 17 18970610 - 0.64 0.52 0.12 0.004033
cg03310594 7 22704316 - 0.82 0.69 0.13 2.34E-05
cg05854694 14 61123243 - 0.12 0.22 −0.10 0.000358
cg12384499 15 89949617 - 0.19 0.31 −0.11 0.004033
cg22509113 2 91777482 - 0.41 0.51 −0.10 0.004033
cg10495084 15 96889416 - 0.24 0.36 −0.12 0.004033
cg18008019 13 100641646 - 0.10 0.23 −0.12 0.03549
Maltby et al. Clinical Epigenetics  (2015) 7:118 Page 3 of 6
apoptosis and inflammation. FTL is a component of fer-
ritin, and defects in this subunit are associated with other
neurodegenerative diseases where mutations result in
accumulation of iron in the brain [9]. Relapsing–remit-
ting multiple sclerosis (RRMS) patients have increased
iron deposits in their grey matter as compared to
healthy controls; thus, misregulation of FTL could be
important in disease pathology [10, 11]. Mutations in
DCAF4 are associated with leucocyte telomere length,
and there is evidence that shortened telomere length in
Table 1 MS-associated CpGs in CD8+ T cells (Continued)
cg12093775 13 112548065 - 0.15 0.26 −0.11 0.000358
cg12787323 10 119494959 - 0.16 0.27 −0.11 0.004033
cg22792862 14 67827087 EIF2S1 1st exon 0.23 0.38 −0.15 0.004033
cg08969532 10 99790438 CRTAC1 1st exon 0.05 0.15 −0.10 0.004033
cg18185028 3 154042079 DHX36 1st exon 0.30 0.41 −0.11 0.000358
cg23059965 19 50655862 C19orf41 3′UTR 0.81 0.70 0.11 0.004033
cg02192678 8 1495185 DLGAP2 5′UTR 0.78 0.68 0.11 0.004033
cg02976009 6 32068226 TNXB 5′UTR 0.71 0.59 0.12 0.03549
cg18073471 4 81119198 PRDM8 5′UTR 0.18 0.29 −0.11 0.03549
cg00945810 7 814391 HEATR2 Body 0.67 0.56 0.11 0.03549
cg04875614 4 2008706 WHSC2 Body 0.80 0.69 0.10 2.34E-05
cg26920627 1 7319248 CAMTA1 Body 0.75 0.63 0.12 0.004033
cg26647242 2 30040525 ALK Body 0.78 0.67 0.11 0.004033
cg04605816 20 62092443 KCNQ2 Body 0.83 0.71 0.12 0.004033
cg10944063 2 120233706 SCTR Body 0.58 0.46 0.12 0.004033
cg14595269 7 151216272 RHEB Body 0.14 0.24 −0.10 2.34E-05
cg23720125 5 177097760 LOC202181 Body 0.85 0.73 0.12 0.004033
cg02047661 3 51976883 RRP9 TSS1500 0.64 0.52 0.11 0.004033
cg07925549 12 52828840 KRT75 TSS1500 0.75 0.63 0.12 0.03549
cg06697094 17 54911185 DGKE TSS1500 0.16 0.28 −0.12 0.03549
cg18789663 1 242688591 PLD5 TSS1500 0.09 0.20 −0.11 0.03549
cg03468541 14 89029199 ZC3H14 TSS200 0.17 0.30 −0.13 0.004033
cg13526221 8 987389 - 0.79 0.69 0.11 0.004033
cg03313895 4 24803042 - 0.65 0.54 0.10 0.03549
cg19442593 2 26252851 - 0.85 0.74 0.11 0.004033
cg04851089 6 28953923 - 0.39 0.54 −0.15 0.004033
cg24520975 6 31651362 - 0.86 0.75 0.11 0.03549
cg01932076 21 47394659 - 0.18 0.30 −0.12 2.34E-05
cg17555825 5 76924190 - 0.16 0.26 −0.10 0.03549
cg23154781 15 80634195 - 0.81 0.69 0.12 0.004033
cg00792513 6 100066698 - 0.34 0.47 −0.14 0.03549
cg23708569 14 106058450 - 0.63 0.51 0.13 2.34E-05
cg09579989 12 110685438 - 0.81 0.71 0.10 0.03549
cg12077664 12 125145446 - 0.78 0.64 0.14 0.000358
cg24824082 2 133030701 - 0.24 0.35 −0.11 0.000358
Dash indicates intergenic
UTR untranslated region, TSS transcription start site
aProbe ID on 450K chip
bChromosome
cGene annotated to probe
dDifferential-methylated score
ep value for specified probe in CD8+ T cells
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leucocytes is associated with other neurodegenerative
diseases, such as Parkinson and Alzheimer’s disease
[12–14]. In addition, one study found a shorted telo-
mere length in primary progressive MS patients, but
no correlation between RRMS and differing telomere
length has been established [15].
Interestingly, we did not see a cluster of differentially
methylated CpGs within HLA-DRB1 as seen in CD4+ T
cells [5]. It is well known that the HLA region is notori-
ously difficult to investigate with many molecular tech-
niques due to increased genetic variation. To minimise
the possibility that our observed methylation profile was
due to the probes in this region not meeting QC, we
used targeted pyrosequencing on available case and con-
trol DNA samples. This assay covered seven of the ten
differentially methylated CpGs identified in our previous
study, but due to high sequence variability, only five of
the seven sites returned data. We calculated the median
beta values across the five CpG sites using the K–S test.
Results showed that the median methylation level in the
cases (median = 3.6) and controls (median = 3.6) was not
significantly different (p = 0.72). This supports a conclu-
sion that this MS-related DMR at HLA-DRB1 does not
exist in CD8+ T cells but is unique to CD4+ T cells.
A recent study by Bos et al. (2015) also found no
major effect loci or clusters of differentially methylated
CpGs in the CD8+ T cells of MS patients. However, of
the top 40 CpG sites, none overlaps with the top 79 sites
found in our study. In addition, we found that approxi-
mately half the differentially methylated sites were
hypermethylated. This is also in contrast to Bos et al.,
who found nearly 95 % of sites were hypermethylated in
CD8+ T cells. Unlike Bos et al., we chose not to filter
out probes that are known to contain SNPs. We rea-
soned that any false positive signals exclusively due to
SNP effects would be subsequently identified by geno-
typing at the key loci. In support of this notion, pyrose-
quencing of the key HLA-DRB1 locus did not alter our
array-based findings. Additionally, we did not observe a
signal at the HLA-DRB1 locus in CD8+ T cells but did
in CD4+ T cells, providing further support that SNPs are
not influencing the findings at this locus.
One important consideration of our study is that the
patients were being, or had been, treated with various
immunomodulatory therapies at the time of recruitment.
In particular, eight patients were being treated with fin-
golimod, which prevents CD4+ lymphocyte egress from
lymphoid tissue. As part of our analysis, we stratified
our case–control analysis based on treatment groups in an
effort to determine whether overall differential methyla-
tion signal may be confounded. None of the patient treat-
ment groups shows a distinct methylation signature,
including fingolimod (data not shown), which supports
the notion that the small number of treated patients in
our cohort is not affecting our results. We do note that
this does not necessarily mean that fingolimod is not act-
ing on the methylome, but we can conclude that the small
number of patients being treated with fingolimod in our
study is not confounding the findings. Future studies will
benefit from treatment-naïve patients or will be limiting
the study to patients on a particular treatment group.
In this study, we identified 79 CpGs showing minor
association with MS. None of these hits was observed in
the CD4+ T cells from the same cohort, including the
major CD4+ DMR at HLA-DRB1. All genome-wide
DNA methylation studies to date have used relatively
small sample sizes. This has resulted in identification of
large-effect regions only. Large-scale studies are needed
to identify minor-effect DMRs. Future studies should also
examine the functional consequences of these changes
through transcript analysis. Primarily, the results of this
study highlight the need to focus on individual cell
types when assessing DNA methylation associated with
MS susceptibility.
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